Pilot Study of Neoantigen Profiling in Patients with Melanoma Treated with PD-1 Blockade

This research study is designed to better understand the molecular determinants of response to immunotherapies including pembrolizumab and nivolumab. We hope to learn the relevance of tumor neoantigens in the recognition of cancer cells by the immune system. The ultimate goal is to rank and filter these neoantigens and correlate with response to immunotherapies.

Inova Schar Cancer Institute
8081 Innovation Park Drive
Fairfax, VA 22031
A department of Inova Fairfax Hospital

• >= 18 years
• Stage III or IV melanoma
• Underwent treatment with anti-PD-1 therapy (pembrolizumab or nivolumab) for at least 12 weeks with available radiologic response data
• For patients prospectively consenting able to provide informed consent for blood collection
• For patients eligible but deceased, a waiver of consent is requested to obtain only existing tissue previously collected for clinical purposes